Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) shares were up 7.2% on Monday . The company traded as high as $9.48 and last traded at $9.41. Approximately 94,007 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 323,589 shares. The stock had previously closed at $8.78.
Upstream Bio Stock Performance
The firm's 50-day moving average is $7.84.
Hedge Funds Weigh In On Upstream Bio
Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in shares of Upstream Bio during the 4th quarter worth $25,000. US Bancorp DE bought a new position in Upstream Bio during the fourth quarter worth about $27,000. Legal & General Group Plc bought a new position in Upstream Bio during the fourth quarter worth about $28,000. Summit Investment Advisors Inc. purchased a new position in shares of Upstream Bio in the fourth quarter worth about $30,000. Finally, Tower Research Capital LLC TRC bought a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $47,000.
Upstream Bio Company Profile
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Recommended Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
